The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera

Ayalew Tefferi, Terra L. Lasho, Susan M. Schwager, Jacob S. Strand, Michelle Elliott, Ruben Mesa, Chin Yang Li, Martha Wadleigh, Stephanie J. Lee, D. Gary Gilliland

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

BACKGROUND. Several studies have recently reported on the occurrence of a JAK2V617F mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study. METHODS. In a single institutional study, mutation screening for JAK2V617F was performed in DNA derived from archived blood granulocytes from 63 consecutive patients with PV in whom current diagnostic criteria were strictly applied and the diagnosis confirmed by bone marrow histology. RESULTS. The JAK2V617F mutant allele was detected in 58 of the 63 patients (92%) with 21% homozygosity. The clinical phenotype of the five patients with the wild-type allele was otherwise typical for the disease. A statistical comparison between JAK2V617F heterozygotes (n = 45 patients) and homozygotes (n = 13 patients) did not reveal any significant associations with regard to age, gender, leukocyte or platelet count at the time of diagnosis, duration of disease, or the incidences of thrombosis or bleeding. However, compared with their heterozygote counterparts, JAK2V617F homozygote patients displayed a significantly higher hemoglobin level at the time of diagnosis (P = 0.001), an increased incidence of pruritus (69% vs. 38%; P = 0.04), a higher rate of fibrotic transformation (23% vs. 2%; P = 0.009), and higher PRV-1 transcript levels in their blood granulocytes (P = 0.07). CONCLUSIONS. The results of the current clinical study support previous laboratory observations that link JAK2V617F with the PV phenotype by demonstrating a mutant allele dose effect on erythrocytosis and clinical and laboratory features characteristic of PV.

Original languageEnglish (US)
Pages (from-to)631-635
Number of pages5
JournalCancer
Volume106
Issue number3
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint

Polycythemia Vera
Phenotype
Alleles
Homozygote
Heterozygote
Granulocytes
Polycythemia
Mutation
Incidence
Myeloid Cells
Pruritus
Platelet Count
Leukocyte Count
Histology
Hemoglobins
Thrombosis
Bone Marrow
Observation
Hemorrhage
DNA

Keywords

  • Heterozygotes
  • Homozygotes
  • JAK2
  • Mutant allele
  • Myeloid cells
  • Polycythemia vera

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tefferi, A., Lasho, T. L., Schwager, S. M., Strand, J. S., Elliott, M., Mesa, R., ... Gilliland, D. G. (2006). The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera. Cancer, 106(3), 631-635. https://doi.org/10.1002/cncr.21645

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera. / Tefferi, Ayalew; Lasho, Terra L.; Schwager, Susan M.; Strand, Jacob S.; Elliott, Michelle; Mesa, Ruben; Li, Chin Yang; Wadleigh, Martha; Lee, Stephanie J.; Gilliland, D. Gary.

In: Cancer, Vol. 106, No. 3, 01.02.2006, p. 631-635.

Research output: Contribution to journalArticle

Tefferi, A, Lasho, TL, Schwager, SM, Strand, JS, Elliott, M, Mesa, R, Li, CY, Wadleigh, M, Lee, SJ & Gilliland, DG 2006, 'The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera', Cancer, vol. 106, no. 3, pp. 631-635. https://doi.org/10.1002/cncr.21645
Tefferi, Ayalew ; Lasho, Terra L. ; Schwager, Susan M. ; Strand, Jacob S. ; Elliott, Michelle ; Mesa, Ruben ; Li, Chin Yang ; Wadleigh, Martha ; Lee, Stephanie J. ; Gilliland, D. Gary. / The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera. In: Cancer. 2006 ; Vol. 106, No. 3. pp. 631-635.
@article{e0f34c82dceb4be8aa3e5b7d7232c166,
title = "The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera",
abstract = "BACKGROUND. Several studies have recently reported on the occurrence of a JAK2V617F mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study. METHODS. In a single institutional study, mutation screening for JAK2V617F was performed in DNA derived from archived blood granulocytes from 63 consecutive patients with PV in whom current diagnostic criteria were strictly applied and the diagnosis confirmed by bone marrow histology. RESULTS. The JAK2V617F mutant allele was detected in 58 of the 63 patients (92{\%}) with 21{\%} homozygosity. The clinical phenotype of the five patients with the wild-type allele was otherwise typical for the disease. A statistical comparison between JAK2V617F heterozygotes (n = 45 patients) and homozygotes (n = 13 patients) did not reveal any significant associations with regard to age, gender, leukocyte or platelet count at the time of diagnosis, duration of disease, or the incidences of thrombosis or bleeding. However, compared with their heterozygote counterparts, JAK2V617F homozygote patients displayed a significantly higher hemoglobin level at the time of diagnosis (P = 0.001), an increased incidence of pruritus (69{\%} vs. 38{\%}; P = 0.04), a higher rate of fibrotic transformation (23{\%} vs. 2{\%}; P = 0.009), and higher PRV-1 transcript levels in their blood granulocytes (P = 0.07). CONCLUSIONS. The results of the current clinical study support previous laboratory observations that link JAK2V617F with the PV phenotype by demonstrating a mutant allele dose effect on erythrocytosis and clinical and laboratory features characteristic of PV.",
keywords = "Heterozygotes, Homozygotes, JAK2, Mutant allele, Myeloid cells, Polycythemia vera",
author = "Ayalew Tefferi and Lasho, {Terra L.} and Schwager, {Susan M.} and Strand, {Jacob S.} and Michelle Elliott and Ruben Mesa and Li, {Chin Yang} and Martha Wadleigh and Lee, {Stephanie J.} and Gilliland, {D. Gary}",
year = "2006",
month = "2",
day = "1",
doi = "10.1002/cncr.21645",
language = "English (US)",
volume = "106",
pages = "631--635",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 V617F in polycythemia vera

AU - Tefferi, Ayalew

AU - Lasho, Terra L.

AU - Schwager, Susan M.

AU - Strand, Jacob S.

AU - Elliott, Michelle

AU - Mesa, Ruben

AU - Li, Chin Yang

AU - Wadleigh, Martha

AU - Lee, Stephanie J.

AU - Gilliland, D. Gary

PY - 2006/2/1

Y1 - 2006/2/1

N2 - BACKGROUND. Several studies have recently reported on the occurrence of a JAK2V617F mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study. METHODS. In a single institutional study, mutation screening for JAK2V617F was performed in DNA derived from archived blood granulocytes from 63 consecutive patients with PV in whom current diagnostic criteria were strictly applied and the diagnosis confirmed by bone marrow histology. RESULTS. The JAK2V617F mutant allele was detected in 58 of the 63 patients (92%) with 21% homozygosity. The clinical phenotype of the five patients with the wild-type allele was otherwise typical for the disease. A statistical comparison between JAK2V617F heterozygotes (n = 45 patients) and homozygotes (n = 13 patients) did not reveal any significant associations with regard to age, gender, leukocyte or platelet count at the time of diagnosis, duration of disease, or the incidences of thrombosis or bleeding. However, compared with their heterozygote counterparts, JAK2V617F homozygote patients displayed a significantly higher hemoglobin level at the time of diagnosis (P = 0.001), an increased incidence of pruritus (69% vs. 38%; P = 0.04), a higher rate of fibrotic transformation (23% vs. 2%; P = 0.009), and higher PRV-1 transcript levels in their blood granulocytes (P = 0.07). CONCLUSIONS. The results of the current clinical study support previous laboratory observations that link JAK2V617F with the PV phenotype by demonstrating a mutant allele dose effect on erythrocytosis and clinical and laboratory features characteristic of PV.

AB - BACKGROUND. Several studies have recently reported on the occurrence of a JAK2V617F mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study. METHODS. In a single institutional study, mutation screening for JAK2V617F was performed in DNA derived from archived blood granulocytes from 63 consecutive patients with PV in whom current diagnostic criteria were strictly applied and the diagnosis confirmed by bone marrow histology. RESULTS. The JAK2V617F mutant allele was detected in 58 of the 63 patients (92%) with 21% homozygosity. The clinical phenotype of the five patients with the wild-type allele was otherwise typical for the disease. A statistical comparison between JAK2V617F heterozygotes (n = 45 patients) and homozygotes (n = 13 patients) did not reveal any significant associations with regard to age, gender, leukocyte or platelet count at the time of diagnosis, duration of disease, or the incidences of thrombosis or bleeding. However, compared with their heterozygote counterparts, JAK2V617F homozygote patients displayed a significantly higher hemoglobin level at the time of diagnosis (P = 0.001), an increased incidence of pruritus (69% vs. 38%; P = 0.04), a higher rate of fibrotic transformation (23% vs. 2%; P = 0.009), and higher PRV-1 transcript levels in their blood granulocytes (P = 0.07). CONCLUSIONS. The results of the current clinical study support previous laboratory observations that link JAK2V617F with the PV phenotype by demonstrating a mutant allele dose effect on erythrocytosis and clinical and laboratory features characteristic of PV.

KW - Heterozygotes

KW - Homozygotes

KW - JAK2

KW - Mutant allele

KW - Myeloid cells

KW - Polycythemia vera

UR - http://www.scopus.com/inward/record.url?scp=31544477194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31544477194&partnerID=8YFLogxK

U2 - 10.1002/cncr.21645

DO - 10.1002/cncr.21645

M3 - Article

VL - 106

SP - 631

EP - 635

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -